Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 15/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129549 | 1.00 | ATM (0.50) | ATMKMT2AMEN1F11KLKB1 | |
| SCHEMBL4142800 | 0.86 | ATM (0.48) | ATMKMT2AMEN1F11KLKB1 | |
| SCHEMBL4142802 | 0.86 | ATM (0.48) | ATMKMT2AMEN1F11KLKB1 | |
| SCHEMBL4142472 | 0.86 | KMT2A (0.56) | ATMKMT2AMEN1F11KLKB1 | |
| SCHEMBL4142475 | 0.86 | KMT2A (0.56) | ATMKMT2AMEN1F11KLKB1 | |
| SCHEMBL5594023 | 0.85 | ACACB (0.43) | ATMKMT2AMEN1 | |
| SCHEMBL8237611 | 0.84 | KMT2A (0.48) | ATMKMT2AMEN1F11KLKB1 | |
| SCHEMBL392733 | 0.79 | F11 (0.72) | ATMKMT2AMEN1F11KLKB1 | |
| SCHEMBL392785 | 0.79 | F11 (0.72) | ATMKMT2AMEN1F11KLKB1 | |
| SCHEMBL13524383 | 0.79 | F11 (0.67) | ATMKMT2AMEN1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | ATM 690/4885KMT2A 2659/4885MEN1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.